This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Hyperion Therapeutics Announces First Quarter 2013 Operating Results

Revenue

RAVICTI net sales were $0.8 million for the first quarter of 2013, representing orders received by patients post-approval. The FDA granted approval of RAVICTI on February 1, 2013.

Operating Expenses

Cost of goods sold was $68,000 for the first quarter of 2013. Cost of goods sold related to the sales of RAVICTI is not representative of Hyperion's future expectations of this expense as manufacturing related expenses associated with RAVICTI sales during the first quarter of 2013 were recorded to research and development expenses in periods prior to approval.

Research and development expenses for the first quarter of 2013 were $1.8 million compared with $8.9 million for the same period in 2012. The decrease was primarily due to $5.7 million in expenses incurred in connection with the purchase of RAVICTI in 2012 as well as a decrease in clinical development costs primarily due to the completion of our HE Phase II trial in 2012. Total research and development stock-based compensation expense for the first quarter of 2013 was $0.1 million compared with $37,000 for the same period in 2012.

Selling, general and administrative expenses for the first quarter 2013 were $7.9 million compared to $2.3 million for the same period of 2012. The increase in the first quarter compared to the same period last year was primarily due to an increase in employee-related costs as a result of new hires in the commercial organization, increases in consulting expenses and other commercial and administrative related infrastructure expenses pertaining to the commercialization of RAVICTI. Total selling, general and administrative stock-based compensation expense for the first quarter of 2013 was $0.4 million compared with $41,000 for the same period in 2012.

As of March 31, 2013, Hyperion had cash and cash equivalents of $102.7 million, an increase of $52.8 million from December 31, 2012. The increase is primarily due to net proceeds of $63.7 million received from the Company's follow-on public offering, partially offset by cash used in operations of $10.8 million.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,119.23 +22.33 0.12%
S&P 500 2,098.77 +0.24 0.01%
NASDAQ 4,973.6660 +6.5250 0.13%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs